The European Union’s trade in medicinal and pharmaceutical products reached unprecedented levels in 2025, delivering a record surplus of €220.5 billion. The surge was driven
by strong export growth, underscoring Europe’s dominant position in the global pharmaceutical market.
According to the latest data, EU exports of medicines and pharmaceutical goods climbed to €366.2 billion in 2025, marking a sharp 16% increase compared to the previous year. Imports also rose significantly, jumping 21% to €145.7 billion. Despite the faster growth in imports, the bloc maintained a substantial trade surplus, reflecting sustained global demand for European-made pharmaceuticals.
Ireland emerged as the EU’s leading exporter to non-EU countries, shipping medicinal and pharmaceutical products worth €93.8 billion. Germany followed with €67.9 billion, while Belgium ranked third with €38.5 billion in exports. These figures highlight the continued concentration of pharmaceutical manufacturing and distribution hubs within a handful of member states.
On the import side, Italy became the largest buyer of pharmaceutical goods from outside the EU, with imports totaling €27.5 billion. Belgium and Germany were close behind, importing €24.7 billion and €24.2 billion respectively.
The United States remained the EU’s most important trading partner in this sector. Nearly 44% of all EU pharmaceutical exports were destined for the US, valued at €160.6 billion. Switzerland held its position as the second-largest export market, accounting for €59.7 billion, while the United Kingdom ranked third with €20.6 billion.
Imports showed a similar pattern. The US was again the primary source, supplying €60.1 billion worth of pharmaceutical products to the EU—over 40% of total imports. Switzerland followed with €41.4 billion, and China accounted for €13.1 billion, reinforcing its role as a key supplier in the global pharmaceutical supply chain.
The data reflects both the resilience and growing strategic importance of the pharmaceutical sector within the EU economy, particularly amid increasing global demand for medical products and innovation-driven healthcare solutions. Photo by Trougnouf, Wikimedia commons.